Adaptive trial design is shaping the future of oncology research. In our latest guide, Ergomed experts explore how adaptive dose-escalation models such as BOIN and CRM are redefining early-phase oncology studies—enhancing precision, patient safety, and regulatory alignment under FDA’s Project Optimus. From traditional 3+3 models to advanced Bayesian approaches, discover how data-driven design strategies enable … Continued